Researchers compare the safety and feasibility of an adaptive deep brain stimulation (aDBS) system to a conventional DBS system for Parkinson’s disease.
Moderna posts reported net loss of $3.6bn in Q3 earnings – Pharmaceutical Technology
Moderna has six Phase III programmes underway, including one for a CMV vaccine, which has completed enrolment. Credit: Tada Images via www.shutterstock.com. Moderna has posted